The FDA accepted Bioverativ's investigative new drug application for BIVV003 as a treatment for sickle cell disease. The acceptance of the IND allows the company to launch a Phase I/II study to evaluate the safety of the candidate in adult patients with the disease.
Bioverativ's IND for sickle cell disease drug accepted by FDA
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.